Drug
Pemetrexed
Pemetrexed: highest development phase Post-Market, developed by Eli Lilly, Hikma. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Eli Lilly, Hikma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Pemetrexed NCT03460678 | Post-Market | Carcinoma, Non-Small-Cell Lung |
| pemetrexed NCT00887549 | Phase 2 | Non-Small Cell Lung Cancer |
| Pemetrexed NCT00102219 | Phase 2 | Breast Cancer |
| Pemetrexed NCT01139775 | Phase 1/2 | Non Small Cell Lung Cancer |
Latest
No recent events.
Follow Pemetrexed on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.